The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor

Journal of Molecular Cell Biology

Volumn 4, Issue 3, 2012, Pages 153-163

  Won, Jae Kyung ^a,b   Yang, Hee Won ^a   Shin, Sung Young ^a   Lee, Jong Hoon ^a   Heo, Won Do ^a   Cho, Kwang Hyun ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Seoul National University Cancer Hospital   (South Korea)

Author keywords

biochemical control analysis; ERK pathway; mathematical model; MEK inhibitor; PI3K pathway; resistance; robustness; systems biology

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; B RAF KINASE; BINDING PROTEIN; GRB2 ASSOCIATED BINDING PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; SOS PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCHEMISTRY; CANCER RESISTANCE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME REPRESSION; GENE MUTATION; NEGATIVE FEEDBACK; ONCOGENE; POSITIVE FEEDBACK; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SIMULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEK293 CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 84861871300     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mjs021     Document Type: Article

References (36)

1. Adjei, A.A., Cohen, R.B., Franklin, W., et al. (2008). Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139-2146.
2. Borisov, N., Aksamitiene, E., Kiyatkin, A., et al. (2009). Systems-level interactions between insulin-EGF networks amplify mitogenic signaling. Mol. Syst. Biol. 5, 256.
3. Brown, A.P., Carlson, T.C., Loi, C.M., et al. (2007). Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother. Pharmacol. 59, 671-679.
4. Corcoran, R.B., Dias-Santagata, D., Bergethon, K., et al. (2010). BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 3, ra84.
5. Emery, C.M., Vijayendran, K.G., Zipser, M.C., et al. (2009). MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl Acad. Sci. USA 106, 20411-20416.
6. Engelman, J.A., Chen, L., Tan, X., et al. (2008). Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356.
7. Gopal, Y.N., Deng, W., Woodman, S.E., et al. (2010). Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res. 70, 8736-8747.
8. Haura, E.B., Ricart, A.D., Larson, T.G., et al. (2010). A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin. Cancer Res. 16, 2450-2457.
9. Iadevaia, S., Lu, Y., Morales, F.C., et al. (2010). Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res. 70, 6704-6714.
10. Iverson, C., Larson, G., Lai, C., et al. (2009). RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 69, 6839-6847.
11. Janne, P.A., Gray, N., and Settleman, J. (2009). Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. DrugDiscov. 8, 709-723.
12. Kitano, H. (2007). A robustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov. 6, 202-210.
13. Knight, Z.A., Lin, H., and Shokat, K.M. (2010). Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10, 130-137.
14. Lehar, J., Krueger, A., Zimmermann, G., et al. (2008). High-order combination effects and biological robustness. Mol. Syst. Biol. 4, 215.
15. Lemmon, M.A., and Schlessinger, J. (2010). Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134.
16. LoRusso, P.M., Krishnamurthi, S.S., Rinehart, J.J., et al. (2010). Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin. Cancer Res. 16, 1924-1937.
17. Mattoon, D.R., Lamothe, B., Lax, I., et al. (2004). The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. BMC Biol. 2, 2-4.
18. Meads, M.B., Gatenby, R.A., and Dalton, W.S. (2009). Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 9, 665-674.
19. Mendoza, M.C., Er, E.E., and Blenis, J. (2011). The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 36, 320-328.
20. Mirzoeva, O.K., Das, D., Heiser, L.M., et al. (2009). Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 69, 565-572.
21. Montagut, C., Sharma, S.V., Shioda, T., et al. (2008). Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 4853-4861.
22. Nazarian, R., Shi, H., Wang, Q., et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
23. Pacold, M.E., Suire, S., Perisic, O., et al. (2000). Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103, 931-943.
24. Papp, B., Notebaart, R.A., and Pal, C. (2011). Systems-biology approaches for predicting genomic evolution. Nat. Rev. Genet. 12, 591-602.
25. Prahallad, A., Sun, C., Huang, S., et al. (2012). Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103.
26. Rinehart, J., Adjei, A.A., Lorusso, P.M., et al. (2004). Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-smallcell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22, 4456-4462.
27. Rodriguez-Viciana, P., Warne, P.H., Dhand, R., et al. (1994). Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370, 527-532.
28. Shin, S.Y., Yang, H.W., Kim, J.R., et al. (2011). A hidden incoherent switch regulates RCAN1 in the calcineurin-NFAT signaling network. J. Cell Sci. 124, 82-90.
29. Solit, D.B., Garraway, L.A., Pratilas, C.A., et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362.
30. Sordella, R., Bell, D.W., Haber, D.A., et al. (2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167.
31. Suire, S., Hawkins, P., and Stephens, L. (2002). Activation of phosphoinositide 3-kinase gamma by Ras. Curr. Biol. 12, 1068-1075.
32. Wagner, A. (2000). Robustness against mutations in genetic networks of yeast. Nat. Genet. 24, 355-361.
33. Wee, S., Jagani, Z., Xiang, K.X., et al. (2009). PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 69, 4286-4293.
34. Wickenden, J.A., Jin, H., Johnson, M., et al. (2008). Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Oncogene 27, 7150-7161.
35. Wildermuth, M.C. (2000). Metabolic control analysis: biological applications and insights. Genome Biol. 1, REVIEWS1031.
36. Yeh, T.C., Marsh, V., Bernat, B.A., et al. (2007). Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 13, 1576-1583.